Centers for Disease Control, Taipei, Taiwan, ROC.
Antiviral Res. 2010 Dec;88(3):256-62. doi: 10.1016/j.antiviral.2010.09.014. Epub 2010 Sep 24.
In this study, we investigated the frequency of oseltamivir resistance in pandemic (H1N1) 2009 influenza A viruses in Taiwan and characterized the resistant viruses. From May 2009 to January 2010, 1187 pandemic H1N1 virus-positive cases in Taiwan were tested for the H275Y substitution in the neuraminidase (NA) gene that confers resistance to oseltamivir. Among them, eight hospitalized cases were found to be infected with virus encoding the H275Y substitution in their original specimens collected after oseltamivir treatment. The epidemiologic investigation indicated that each of the cases occurred sporadically and there was no evidence of further transmission. We monitored the variation of amino acid residues at position 275 of the NA gene in a series of specimens taken at various time-points and observed that viruses encoding the H275Y substitution differ in their fitness in vivo and in MDCK cells. Phylogenetic analysis indicated that the hemagglutinin (HA) sequences of oseltamivir-resistant pandemic H1N1 viruses exhibited greater diversity than the NA sequences and progressive changes of the HA genes from clade A1 into A2 and from there into clade A3 were observed. The resistant viruses seemed to occur in combination with diverse HA genes and a dominant NA gene. Enzymatic analysis of the viruses revealed that the ratio of NA/HA activities in oseltamivir-resistant viruses was reduced considerably compared to those in wild-type ones.
在这项研究中,我们调查了台湾地区大流行(H1N1)2009 流感 A 病毒中奥司他韦耐药的频率,并对耐药病毒进行了特征分析。2009 年 5 月至 2010 年 1 月,我们对台湾地区 1187 例大流行 H1N1 病毒阳性病例进行了神经氨酸酶(NA)基因中 H275Y 取代检测,该取代赋予了对奥司他韦的耐药性。其中,在 8 例住院病例的原始样本中发现了奥司他韦治疗后编码 H275Y 取代的病毒。流行病学调查表明,每个病例都是散发的,没有进一步传播的证据。我们在一系列不同时间点采集的样本中监测了 NA 基因 275 位氨基酸残基的变异情况,观察到编码 H275Y 取代的病毒在体内和 MDCK 细胞中的适应性存在差异。系统进化分析表明,奥司他韦耐药性大流行 H1N1 病毒的血凝素(HA)序列比 NA 序列具有更大的多样性,并且观察到 HA 基因从 A1 进化分支逐渐变为 A2 和 A3 进化分支。耐药病毒似乎与多样化的 HA 基因和一个主要的 NA 基因同时出现。对病毒的酶分析表明,与野生型相比,奥司他韦耐药病毒的 NA/HA 活性比值大大降低。